The Center for Cellular Engineering (CCE) is working to develop and improve cancer cellular therapies including Dendritic Cell (DC) therapies, chimeric antigen receptor (CAR) T cell therapies and T cell engineered to express T cell receptors (TCRs) specific to tumor antigens. The laboratory is working to improve the methods used to produce Bone Marrow Stromal Cells (BMSCs) and induced pluripotent stem (iPS) cells for regenerative medicine applications. Dendritic cells are an important adjuvant for cancer vaccines. The CCE is currently producing DCs expressing HER2/neu to treat cancer patients whose tumors express this antigen. The lab has discovered that factors in the plasma from some people can inhibit the expression of HER2/neu by DCs. The CCE New Production Management (NPM) laboratory has developed and is manufacturing several CAR T cell therapies. CD22-CAR T cells and CD19/CD22-bispecific T cells are being manufactured in order to treat pediatric patients with B cell leukemia. Manufacturing of CD30-CAR T cells has recently been initiated. These CAR T cells are being used to treat adults with lymphomas. The laboratory has also developed anti-B Cell Maturation Antigen (BCMA) CAR T cells and anti-SLAMF7-CAR T cells to treat patients with multiple myeloma. The laboratory has developed procedures to manufacture CD19/CD22- CAR T cells using a completely automated instrument. Human Papillomavirus (HPV) infection is associated with a number of cancers. The NPM laboratory has developed a method to produce T cells that express a T cell receptor (TCR) that is specific for the HPV-16 oncoprotein E7. These cells will be used to treat patients with HPV-associated cervical and oropharyngeal cancers. The Cell Processing Laboratory is collaborating with investigators in the National Eye Institute to develop methods to manufacture iPS cells from CD34+ cells isolated from the blood and to differentiate the iPS cells in retinal pigment epithelial (RPE) cells. The RPE cells will be used to treat patients with age related macular degeneration.

Agency
National Institute of Health (NIH)
Institute
Clinical Center (CLC)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIACL002120-12
Application #
9986421
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
12
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Clinical Center
Department
Type
DUNS #
City
State
Country
Zip Code
Allen, Elizabeth S; Stroncek, David F; Ren, Jiaqiang et al. (2017) Autologous lymphapheresis for the production of chimeric antigen receptor T cells. Transfusion 57:1133-1141
West, Kamille A; Gea-Banacloche, Juan; Stroncek, David et al. (2017) Granulocyte transfusions in the management of invasive fungal infections. Br J Haematol 177:357-374
Liu, Shutong; de Castro, Luis F; Jin, Ping et al. (2017) Manufacturing Differences Affect Human Bone Marrow Stromal Cell Characteristics and Function: Comparison of Production Methods and Products from Multiple Centers. Sci Rep 7:46731
Stroncek, David F; Ren, Jiaqiang; Lee, Daniel W et al. (2016) Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells. Cytotherapy 18:893-901
Anand, Ankit; Anandi, Prathima; Jain, Natasha A et al. (2016) CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantation. Support Care Cancer 24:815-822
Ali, Syed Abbas; Shi, Victoria; Maric, Irina et al. (2016) T cells expressing an anti-B-cell-maturation-antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood :
Sabatino, Marianna; Hu, Jinhui; Sommariva, Michele et al. (2016) Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood 128:519-28
Merchant, Melinda S; Bernstein, Donna; Amoako, Martha et al. (2016) Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas. Clin Cancer Res 22:3182-91
Stroncek, David F; Tran, Minh; Frodigh, Sue Ellen et al. (2016) Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates. Transfusion 56:511-7
Shaw, Bronwen E; Logan, Brent R; Kiefer, Deidre M et al. (2015) Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. Biol Blood Marrow Transplant 21:1830-8

Showing the most recent 10 out of 51 publications